Clinical Pearls and Future Perspectives in Advanced NSCLC
The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.
Read More
Antibody-Drug Conjugates in EGFR-Mutant NSCLC
The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.
Read More
MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond
A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.
Read More
Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond
Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.
Read More
MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC
The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.
Read More
FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC
Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.
Read More
First-Line Treatment for EGFR-Mutant Advanced Lung Cancer
A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.
Read More
A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Read More
TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC
Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.
Read More
Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape
The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Read More
EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
Read More
Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
Read More
Educating Community Specialists on Evolving Treatment Landscape
Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.
Read More
Future Outlook for Treating Breast and Lung Cancers
Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.
Read More
TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
Read More
NSCLC: PD-L1 Expression and Treatment Decision-Making
Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.
Read More
Future Directions in Gastric Cancer Treatment
Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.
Read More
Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
Read More
First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).
Read More
Dr Levy on the Ongoing Development of TROP-2 ADCs in NSCLC
November 14th 2023Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.
Read More
TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Read More
Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
Read More
Managing T-DXd Toxicities in Gastric Cancer
Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
Read More
Gastric Cancer Treatment: T-DXd
A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
Read More
Management of ADC Toxicities in Lung Cancer
A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.
Read More
Antibody-Drug Conjugates in Lung Cancer
A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.
Read More
Toxicity Management for T-DM1 and T-DXd in Breast Cancer
Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].
Read More